STEP-WISE APPROACH TO INITIATING HEPATITIS C VIRUS (HCV) TREATMENT IN PRIMARY CARE SETTINGS

STEP 1: PATIENT SCREENING

Testing Recommendations for HCV Infection https://www.hcvguidelines.org/evaluate/testing-and-linkage

Universal Screening	All adults once per lifetime & all pregnant women once per pregnancy
One-Time Screening	Under 18 with increased risk of HCV infection or exposure
Periodic Repeat Screening	Offered to all persons with increased risk of HCV infection
Annual Screening	Recommended for persons who inject drugs, HIV-infected men who have unprotected sex with men, men who have sex with men taking pre-exposure prophylaxis (PrEP)

STEP 2: DIAGNOSTIC TESTING

Order HCV Antibody with Reflex to RNA Testing

Interpretation of Results of Tests for HCV infection https://www.cdc.gov/hepatitis/hcv/labtesting.htm

- *If HCV Antibody is non-reactive, then no further action required*
- *If HCV Antibody is reactive, but HCV RNA is not detected, then no further action required in most cases*
- *If HCV Antibody is reactive, AND HCV RNA is detected, then proceed to step 3*

STEP 3: PRE-TREATMENT ASSESSMENT

Recommended Assessments Prior to Starting DAA therapy https://www.hcvguidelines.org/evaluate/monitoring

Rule out Decompensated Cirrhosis	FIB-4 score; CTP score	**If hepatic complications present, consult with a hepatologist, gastroenterologist, or infectious disease specialist.**
Determine baseline details of HCV infection	HCV viral load	Genotyping recommended for cirrhotic patients if not prescribing a pangenotypic DAA regimen.
HBV & HIV Status	HBsAG; HBsA; HBcA	Recommended that specialist be consulted prior to treatment for patient with documented HIV or HBV coinfection
HCV Treatment Experience	Patient history	>4 weeks of prior treatment **consult with a hepatologist, gastroenterologist, or infectious disease specialist**
Medication Review	Med reconciliation; drug-drug interactions	University of Liverpool free interaction checker https://www.hep-druginteractions.org/
Laboratory Testing	CBC, ALT, AST, eGFR	Complete within three months of treatment initiation. Pregnancy testing also recommended.
Comorbid conditions	Patient history	Treatment is not medically appropriate for patients with a life expectancy of less than 1 year.

STEP 4: DIRECT ACTING ANTIVIRAL (DAA) DRUG SELECTION

Treatment Naive Patient Without Cirrhosis https://www.hcvguidelines.org/treatment-naive/simplified-treatment

- Glecaprevir (300 mg) / pibrentasvir (120 mg) (Mavyret) to be taken with food for a duration of 8 weeks
- Sofosbuvir (400 mg) / velpatasvir (100 mg) for a duration of 12 weeks

Treatment Naïve Patient With Compensated Cirrhosis
https://www.hcvguidelines.org/treatment-naive/simplified-treatment-compensated-cirrhosis

- **Genotype 1-6**
  Glecaprevir (300 mg) / pibrentasvir (120 mg) to be taken with food for a duration of 8 weeks
- **Genotype 1, 2, 4, 5, or 6**
  Sofosbuvir (400 mg) / velpatasvir (100 mg) for a duration of 12 weeks
- **Genotype 3 (requires baseline NS5A resistance-associated substitution (RAS) testing)**
  Without Y93H: Sofosbuvir (400 mg) / velpatasvir (100 mg) for a duration of 12 weeks
  With Y93H: Refer to HCV guidelines for treatment recommendations.

STEP-WISE APPROACH TO INITIATING HEPATITIS C VIRUS (HCV) TREATMENT IN PRIMARY CARE SETTINGS

STEP 5: COORDINATE CASE MANAGEMENT

Case Management Requirements of Oregon Health Authority (OHA)

All members with coverage through Oregon Medicaid or a CCO (such as UHA) must be offered case management at the start of HCV treatment with goals including:

** Adherence to medication regimen*
** Mitigation of barriers to treatment*
** Support for patients and provider*
** Compliance with viral load testing*
** Collection of data for state program evaluation*
** Prevention of treatment interruption or delay*

Umpqua Health Alliance

The UHA Hepatitis C Case Management Referral Form must be completed and faxed to 541-229-8081
https://www.umpquahealth.com/case-management/

STEP 6: INITIATE PRIOR AUTHORIZATION REQUEST

Prior authorization for DAA treatment will be required by most insurance plans.

- UHA prior authorization criteria and the specific Hepatitis C Prior Authorization Form are available online: https://www.umpquahealth.com/pharmacy-services/
- Prescriptions must be sent to UHA's specialty service, MedImpact Direct Specialty Hub, by faxing their prescription form to 888-807-5716. Link to form: https://www.medimpactdirect.com/static/MedImpactDirect-Referral%20Form.pdf**.** The medications will be delivered to the member via mail.
- *NOTE: Commercial insurance plans and Medicare Part D provider may have different approval requirements.*

STEP 7: FOLLOW UP TESTING

Monitoring Patients During Treatment

- Patients taking diabetes medications: monitor for hypoglycemia
- Patients taking warfarin: monitor INR for subtherapeutic anticoagulation
- No laboratory monitoring is required for other patients during treatment

Post Treatment Testing (12 weeks after therapy completion)

- SVR & hepatic function panel: Completed to confirm HCV RNA is undetectable and transaminase normal.
  - SVR achieved: No liver-related follow up required for noncirrhotic patients who achieve SVR: advise alcohol abstinence and counsel regarding risk behavior avoidance
  - SVR not achieved: Refer to specialist to evaluate re-treatment option

ADDITIONAL RESOURCES

TRAINING OPPORTUNITIES

Hepatitis C Online
https://www.hepatitisc.uw.edu/

ECHO
https://connect.oregonechonetwork.org

GUIDELINES & RESOURCES

AASLD/IDSA
https://www.hcvguidelines.org/
https://www.hcvguidelines.org/treatment-naive/simplified-treatment-compensated-cirrhosis
https://www.hcvguidelines.org/treatment-naive/simplified-treatment

Centers for Disease Control and Prevention (CDC)
https://www.cdc.gov/hepatitis/hcv/index.htm

UMPQUA HEALTH ALLIANCE

Hepatitis C Prior Authorization and Case Management Referral Form

Fax this completed form to 541.677.5881

**** Required Field***

Date of Request: _____/_____/________

MEMBER INFORMATION		
*Member Name:	*Member ID:	*Member DOB:
PROVIDER INFORMATION		
*Provider Name:	MD ☐ DO ☐ FNP ☐ NP ☐ PA ☐	*NPI:
*Office Contact Person:	*Phone #:	*Fax #:
MEDICATION INFORMATION		
*Drug name, strength, and form:	*Directions:	*Qty per Day:
*Expected Length of Treatment:		
DIAGNOSIS INFORMATION		
*Diagnosis Code(s):		

DOCUMENTATION

Please provide the following information and all related documents:

*Is expected survival from non-HCV-associated morbidities more than 1 year? ☐ Yes ☐ No Date: _________________

*Does the patient have a history of HCV Treatment? ☐ Yes ☐ No Drug Regimen: _______________________________

- If past treatment was failed, was adherence with medication a concern: ☐ Yes ☐ No ☐ Not sure

HCV Genotype (drawn <3 years, if applicable to regimen)	Date:	Result:
*HBV Status	Date:	Result:
HIV Status	Date:	Result:
Baseline NS5a resistance test (if applicable to regimen)	Date:	Result:

*Cirrhosis Status: Present (☐ Compensated ☐ Decompensated) ☐ Absent (Non-cirrhotic)

*Does the patient have complications of cirrhosis, or other hepatic manifestations? ☐ Yes ☐ No

- If yes, explain:____

Child-Pugh Score (if applicable to regimen):__________________________

Stage of Fibrosis	Method of testing (i.e., biopsy, etc.):	Date:	Result:

Does the patient have any drug interactions that have been addressed? ☐ Yes ☐ No

- If yes, explain: ____

***UHA Case Management:** Is there attestation that the patient and provider will comply with UHA case management to promote the best possible outcome for the patient and adhere to monitoring requirements required by the Oregon Health Authority, including measuring and reporting of a post-treatment viral load OR is there attestation from the patient and provider that they have opted out of UHA case management? ☐ Yes ☐ No

Questions? For assistance with this form, call UHA Clinical Pharmacy Services at 541-672-1685 or UHA Case Management at 541.464.4413

MedImpact
Direct Specialty™

Specialty Medication Referral Form

Fax (888) 807-5716

Toll-Free Phone (877) 391-1103

Date Needed: ______________

Note: This form is intended for prescriber use only. If faxed, the fax must come from MD office or hospital (should not be faxed by patient).

Patient Information

Last Name	First Name	Date of Birth	Gender ☐ M ☐ F
Home Phone	Work or Mobile Phone	Email Address (Email used for order status updates)	
Address			
City		State	Zip Code

Patient Insurance Information

Medical Insurance (Please include copy of front and back of card)	Prescription Card Phone
Subscriber Name	
Policy #	BIN/PCN #
Medicare Number	Medicaid Number
Relationship to Patient ☐ Self ☐ Other ___________________	Prescription Card ☐ Yes ☐ No

Clinical Information

Medicare Number		Medicaid Number	
Patient Weight _____________ ☐ lbs ☐ kg (check one)	Height ___________________	☐ Patient is New to Therapy ☐ Patient is Restarting Therapy ☐ Patient is Currently on Therapy (Start Date: _____________)	
Allergies		Diagnosis	ICD-10
Deliver to: ☐ Patient's Home ☐ Prescriber Office ☐ Other ____			

IMPORTANT WARNING: This is intended for the use of the person or entity to whom it is addressed and contains sensitive, confidential information, the disclosure of which may be governed by federal and/or state law. If you are not the intended recipient, or responsible for delivering it to the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.

Copyright © 2016 MedImpact Direct, LLC. All rights reserved.

Prescriber Information

Prescriber Last Name	Prescriber First Name	☐ MD ☐ DO ☐ NP ☐ PA

Prescriber Address

City	State	Zip Code

Phone	Fax	Backline Phone Number

License #	NPI #	UPIN #	DEA #

Office Contact	Supervising Physician (if applicable)

Prescription: Write prescription here and fax to MedImpact Direct Specialty.

Patient's Name

Patient's Date of Birth

Prescriber's Signature

I certify that the therapy is medically necessary and that the information above is accurate to the best of my knowledge. I authorize MedImpact to act on my behalf as my agent for the limited purposes of transmitting this prescription to the appropriate pharmacy designated by the patient's benefit plan. **Prescriber's Signature Required:**

X

Generic Substitution Permitted

X

Dispense As Written

Printed Name

Date:

☐ **Hold shipment until notified by prescriber**

CONFIDENTIAL HEALTH INFORMATION: This form contains health information protected under federal and state confidentiality laws, including but not limited to the Health Insurance Portability and Accountability Act and its implementing regulations (HIPAA). I certify that I have received the appropriate authorization from the patient, if required, and met any other applicable requirements imposed under federal and/or state law, including but not limited to HIPAA, needed to send this information to MedImpact Direct Specialty HUB (MedImpact) and its contracted pharmacies for the purposes of verifying the patient's insurance coverage and providing information on appeals for denied claims.

Prescriber must manually sign (rubber stamps, signature by other office personnel for the prescriber, and computer generated signatures will not be accepted).

Copyright © 2016 MedImpact Direct, LLC. All rights reserved.